| Symbol
| CRKL
| contributors: mct/npt/pgu - updated : 15-01-2020
|
| HGNC name
| v-crk sarcoma virus CT10 oncogene homolog (avian)-like
|
| HGNC id
| 2363
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
| amplification
| --over
|
|
contribute to diverse oncogenic phenotypes in lung cancer, with implications for targeted therapy, and highlight a role of adapter proteins as primary genetic drivers of tumorigenesis  | | tumoral
|
|
| --over
|
| |
correlated with progression and malignant proliferation of breast cancers | | constitutional
|
|
| --other
|
| |
haploinsufficiency of CRKL could be responsible for the etiology of conotruncal heart defects (CTDs) in individuals with nested distal deletions and might act as a genetic modifier of individuals with the typical 3 Mb deletion | | constitutional
|
|
| --low
|
| |
in patients with partial DiGeorge syndrome is associated with impairment of T-cell functions | | tumoral
|
|
| --over
|
| |
in human pancreatic cancers and contributed to pancreatic cancer cell proliferation and invasion through ERK signaling | |
Variant & Polymorphism
| 
| |
| Candidate gene
| DEL22Q11 |
| Marker
| may be a potential molecular target for head and neck squamous cell carcinoma (HNSCC) diagnosis |
|
may serve as a novel prognostic biomarker in gastric cancer |
|
has the potential to serve as a diagnosis and prognosis marker in colon cancer |
|
|
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | head and neck | | |
| novel therapeutic strategies as well as CRK | | cancer | digestive | stomach | |
| has the potential to serve as a molecular therapy target for gastric cancer | | cancer | digestive | colon | |
| therapy target of colon cancer |
| |
|
| mice homozygous for a null mutation exhibit defectsin multiplecranial and cardiac neural crestderivatives, similar to the clinical manifestations of DG/VCFS |